Psych CASC / OSCE · Psychopharmacology — stimulants and ADHD medications
Explaining ADHD medication start, monitoring and diversion risk (CASC)
CASC-style communication station: shared decision on long-acting stimulant or alternatives, CV risk framing, diversion safeguards, growth and school coverage, and follow-up plan.
On this page
Study tools
Target exams
Station instructions (candidate)
You have 7 minutes. Speak with the adolescent and parent. Explain why current IR methylphenidate may be failing school coverage, propose a safer formulation or alternative, address heart and addiction fears with accurate absolute-risk language, outline monitoring (including growth and BP/HR), and set diversion-aware prescribing rules. Avoid jargon without explanation. Do not guarantee cure. Do not dismiss parental cardiac concern given family history — show how you risk-stratify.[1][2][6]
References8ShowHide
- [1]Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry, 2018.PMID 30097390
- [2]Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med, 2011.PMID 22043968
- [3]Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults JAMA, 2011.PMID 22161946
- [4]Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine CNS Drugs, 2017.PMID 28236285
- [5]Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics, 2003.PMID 12509574
- [6]Pliszka S; AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry, 2007.PMID 17581453
- [7]Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled study Biol Psychiatry, 2007.PMID 17631866
- [8]Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry, 2002.PMID 12411225